

**VONJO
(pacritinib)**

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age and older

Diagnoses

Patient must have **ONE** of the following:

1. Primary myelofibrosis
2. Secondary myelofibrosis
3. Post-polycythemia vera myelofibrosis
4. Post-essential thrombocythemia myelofibrosis

AND ALL of the following:

- a. Patient is considered intermediate risk or high-risk
- b. Platelet count < 50 x 10⁹/L
- c. Prescriber agrees to perform a CBC, coagulation testing, and a baseline ECG prior to starting Vonjo
- d. Prescriber agrees to counsel patient to discontinue Vonjo 7 days prior to elective surgery due to the risk of hemorrhage

Prior - Approval Limits

Quantity 360 capsules per 90 days

Duration 6 months

Prior – Approval *Renewal* Requirements

Age 18 years of age and older

Diagnoses

Patient must have **ONE** of the following:

1. Primary myelofibrosis
2. Secondary myelofibrosis
3. Post-polycythemia vera myelofibrosis

**VONJO
(pacritinib)**

4. Post-essential thrombocythemia myelofibrosis

AND ALL of the following:

- a. Patient has had symptomatic improvement
- b. Platelet count < 50 x 10⁹/L
- c. Prescriber agrees to counsel patient to discontinue Vonjo 7 days prior to elective surgery due to the risk of hemorrhage

Prior - Approval *Renewal* Limits

Same as above